| Dr Adam Sharp Cole, MD | |
|
1000 1st Dr Nw, Austin, MN 55912-2941 | |
| (507) 433-7351 | |
| Not Available |
| Full Name | Dr Adam Sharp Cole |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 14 Years |
| Location | 1000 1st Dr Nw, Austin, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285999557 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Health System - Albert Lea And Austin | Albert lea, MN | Hospital |
| Mayo Clinic Health System In Red Wing | Red wing, MN | Hospital |
| Mayo Clinic Health System - Lake City | Lake city, MN | Hospital |
| Mayo Clinic Health System - Cannon Falls | Cannon falls, MN | Hospital |
| Owatonna Hospital | Owatonna, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-lake City | 1951213487 | 49 |
| Mayo Clinic Health System-southeast Minnesota Region | 4385556703 | 573 |
News Archive
Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Writing in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Gary Darmstadt, head of the Family Health Division of the foundation, examines the Jadelle Access Program, announced last week, which aims to "reduce the price of Jadelle and make this effective, long-acting, reversible contraceptive more available to more than 27 million women in the world's poorest countries."
The seventh annual Ready or Not? Protecting the Public's Health from Diseases, Disasters, and Bioterrorism report, released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF), found that the H1N1 flu outbreak has exposed serious underlying gaps in the nation's ability to respond to public health emergencies and that the economic crisis is straining an already fragile public health system.
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164463659 PECOS PAC ID: 1951213487 Enrollment ID: O20031104000095 |
News Archive
Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Writing in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Gary Darmstadt, head of the Family Health Division of the foundation, examines the Jadelle Access Program, announced last week, which aims to "reduce the price of Jadelle and make this effective, long-acting, reversible contraceptive more available to more than 27 million women in the world's poorest countries."
The seventh annual Ready or Not? Protecting the Public's Health from Diseases, Disasters, and Bioterrorism report, released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF), found that the H1N1 flu outbreak has exposed serious underlying gaps in the nation's ability to respond to public health emergencies and that the economic crisis is straining an already fragile public health system.
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891701637 PECOS PAC ID: 4385556703 Enrollment ID: O20031104000408 |
News Archive
Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Writing in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Gary Darmstadt, head of the Family Health Division of the foundation, examines the Jadelle Access Program, announced last week, which aims to "reduce the price of Jadelle and make this effective, long-acting, reversible contraceptive more available to more than 27 million women in the world's poorest countries."
The seventh annual Ready or Not? Protecting the Public's Health from Diseases, Disasters, and Bioterrorism report, released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF), found that the H1N1 flu outbreak has exposed serious underlying gaps in the nation's ability to respond to public health emergencies and that the economic crisis is straining an already fragile public health system.
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545422 PECOS PAC ID: 4688585771 Enrollment ID: O20031110000134 |
News Archive
Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Writing in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Gary Darmstadt, head of the Family Health Division of the foundation, examines the Jadelle Access Program, announced last week, which aims to "reduce the price of Jadelle and make this effective, long-acting, reversible contraceptive more available to more than 27 million women in the world's poorest countries."
The seventh annual Ready or Not? Protecting the Public's Health from Diseases, Disasters, and Bioterrorism report, released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF), found that the H1N1 flu outbreak has exposed serious underlying gaps in the nation's ability to respond to public health emergencies and that the economic crisis is straining an already fragile public health system.
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-fairmont |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366410862 PECOS PAC ID: 4981694981 Enrollment ID: O20040719000142 |
News Archive
Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Writing in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Gary Darmstadt, head of the Family Health Division of the foundation, examines the Jadelle Access Program, announced last week, which aims to "reduce the price of Jadelle and make this effective, long-acting, reversible contraceptive more available to more than 27 million women in the world's poorest countries."
The seventh annual Ready or Not? Protecting the Public's Health from Diseases, Disasters, and Bioterrorism report, released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF), found that the H1N1 flu outbreak has exposed serious underlying gaps in the nation's ability to respond to public health emergencies and that the economic crisis is straining an already fragile public health system.
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System St James |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023177730 PECOS PAC ID: 9537170352 Enrollment ID: O20060509000021 |
News Archive
Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Writing in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Gary Darmstadt, head of the Family Health Division of the foundation, examines the Jadelle Access Program, announced last week, which aims to "reduce the price of Jadelle and make this effective, long-acting, reversible contraceptive more available to more than 27 million women in the world's poorest countries."
The seventh annual Ready or Not? Protecting the Public's Health from Diseases, Disasters, and Bioterrorism report, released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF), found that the H1N1 flu outbreak has exposed serious underlying gaps in the nation's ability to respond to public health emergencies and that the economic crisis is straining an already fragile public health system.
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1538113022 PECOS PAC ID: 1951213487 Enrollment ID: O20070711000490 |
News Archive
Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Writing in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Gary Darmstadt, head of the Family Health Division of the foundation, examines the Jadelle Access Program, announced last week, which aims to "reduce the price of Jadelle and make this effective, long-acting, reversible contraceptive more available to more than 27 million women in the world's poorest countries."
The seventh annual Ready or Not? Protecting the Public's Health from Diseases, Disasters, and Bioterrorism report, released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF), found that the H1N1 flu outbreak has exposed serious underlying gaps in the nation's ability to respond to public health emergencies and that the economic crisis is straining an already fragile public health system.
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1124035282 PECOS PAC ID: 4688585771 Enrollment ID: O20171011003939 |
News Archive
Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Writing in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Gary Darmstadt, head of the Family Health Division of the foundation, examines the Jadelle Access Program, announced last week, which aims to "reduce the price of Jadelle and make this effective, long-acting, reversible contraceptive more available to more than 27 million women in the world's poorest countries."
The seventh annual Ready or Not? Protecting the Public's Health from Diseases, Disasters, and Bioterrorism report, released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF), found that the H1N1 flu outbreak has exposed serious underlying gaps in the nation's ability to respond to public health emergencies and that the economic crisis is straining an already fragile public health system.
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1063435410 PECOS PAC ID: 4385556703 Enrollment ID: O20171011003946 |
News Archive
Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Writing in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Gary Darmstadt, head of the Family Health Division of the foundation, examines the Jadelle Access Program, announced last week, which aims to "reduce the price of Jadelle and make this effective, long-acting, reversible contraceptive more available to more than 27 million women in the world's poorest countries."
The seventh annual Ready or Not? Protecting the Public's Health from Diseases, Disasters, and Bioterrorism report, released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF), found that the H1N1 flu outbreak has exposed serious underlying gaps in the nation's ability to respond to public health emergencies and that the economic crisis is straining an already fragile public health system.
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Adam Sharp Cole, MD 1000 1st Dr Nw, Austin, MN 55912-2941 Ph: (507) 433-7351 | Dr Adam Sharp Cole, MD 1000 1st Dr Nw, Austin, MN 55912-2941 Ph: (507) 433-7351 |
News Archive
Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Writing in the Bill & Melinda Gates Foundation's "Impatient Optimists" blog, Gary Darmstadt, head of the Family Health Division of the foundation, examines the Jadelle Access Program, announced last week, which aims to "reduce the price of Jadelle and make this effective, long-acting, reversible contraceptive more available to more than 27 million women in the world's poorest countries."
The seventh annual Ready or Not? Protecting the Public's Health from Diseases, Disasters, and Bioterrorism report, released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF), found that the H1N1 flu outbreak has exposed serious underlying gaps in the nation's ability to respond to public health emergencies and that the economic crisis is straining an already fragile public health system.
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.
› Verified 7 days ago
Dr. Robert D. Stoffey, D.O. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-434-1092 Fax: 507-434-1477 | |
Richard Mark Bergen, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-434-1092 Fax: 507-434-1477 | |
Don Brandon Stott, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-7351 | |
Dr. Caleb Tsetse, M.D Radiology Medicare: Accepting Medicare Assignments Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-8758 | |
Peter Andrew Lowry, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-7351 | |
Theodore J Hanson, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-7351 | |
Dr. Dorissa Lahner Gursahaney, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1000 1st Dr Nw, Austin, MN 55912 Phone: 507-433-7351 |